CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Co.'s primary focus is on the development of its primary product candidate, DefenCath, for potential commercialization in the U.S. and other main markets. Co. has in-licensed the worldwide rights to develop and commercialize DefenCath and Neutrolin®. DefenCath is an anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition and oncology. The CRMD stock yearly return is shown above.
The yearly return on the CRMD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CRMD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|